Comparative Trial of Agalsidase Alfa and Beta for Fabry Disease
Author Information
Author(s): Vedder Anouk C., Linthorst Gabor E., Houge Gunnar, Groener Johannna E.M., Ormel Els E., Bouma Berto J., Aerts Johannes M.F.G., Hirth Asle, Hollak Carla E.M.
Primary Institution: Academic Medical Center, Amsterdam, The Netherlands
Hypothesis
Is agalsidase alfa clinically superior to agalsidase beta in treating Fabry disease?
Conclusion
There was no significant difference in treatment outcomes between agalsidase alfa and beta for Fabry disease.
Supporting Evidence
- Both treatments were administered at the same dose of 0.2 mg/kg biweekly.
- No significant reduction in left ventricular mass was observed after 12 and 24 months.
- Treatment failure occurred in 8 out of 34 patients.
- Antibodies developed only in male patients receiving either treatment.
- Patients with severe pre-treatment disease had a higher rate of treatment failure.
Takeaway
This study looked at two treatments for a disease called Fabry disease and found that neither treatment worked better than the other.
Methodology
Patients were randomly assigned to receive either agalsidase alfa or beta at a dose of 0.2 mg/kg biweekly for at least 12 months.
Potential Biases
Potential bias due to the open-label design and lack of blinding.
Limitations
The study had a small sample size and a high rate of treatment failure.
Participant Demographics
The study included 34 patients, with an equal distribution of males and females.
Statistical Information
P-Value
0.54
Statistical Significance
p=0.54
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website